Combining cryoablation and radiation therapy for painful bone metastases

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases

This study is testing if combining a freezing treatment with radiation can help people with painful bone cancer feel better compared to just using radiation alone.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: M.D. Anderson Cancer Center (other)
• Drugs / interventions: chemotherapy, immunotherapy, radiation
• Locations: 1 site (Houston, Texas)
• Trial ID: NCT04693377 on ClinicalTrials.gov

What this trial studies

This trial compares the effectiveness of cryoablation combined with stereotactic body radiation therapy (SBRT) against SBRT alone in treating patients suffering from pain due to bone metastases. Cryoablation involves inserting needles to freeze and destroy cancer cells, while SBRT delivers targeted radiation to the tumor. The study aims to assess pain relief, narcotic usage, local tumor control, quality of life, and any adverse effects. Patients will be randomized into two groups, one receiving only SBRT and the other receiving cryoablation followed by SBRT.

Who should consider this trial

Good fit: Ideal candidates include patients with specific types of cancer that have spread to the bones and are experiencing significant pain.

Not a fit: Patients with bone metastases that are not amenable to cryoablation or SBRT may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve pain management for patients with painful bone metastases.

How similar studies have performed: While the combination of cryoablation and SBRT is a novel approach, previous studies have shown success with each treatment individually for pain relief in bone metastases.

Eligibility criteria

Inclusion Criteria:

* Patient must have a primary diagnosis of malignancy and radiographic evidence of bone metastases. Eligible tumor histologies include the following malignancies with low alpha/beta ratios: renal cell carcinoma, urothelial carcinomas, castration-resistant prostate cancer, sarcoma, thyroid carcinoma, colorectal carcinoma, and melanoma
* A target lesion the meets the following criteria:

  * The target lesion must be amenable to both cryoablation and SBRT, as determined by the study principal investigators (PIs)
  * The target lesion must be =\< 7cm
  * The pain due to the target lesion must be at least 4/10 based on the BPI pain scale
  * Pain from the metastatic site must correlate with an identifiable tumor on computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound (US) imaging
* Life expectancy \>= 3 months
* Platelet count \> 50,000/mm\^3 within 6 weeks of screening
* International normalized ratio (INR) \< 1.5 within 6 weeks of screening
* If taking antiplatelet or anticoagulation medication, it must be able to be discontinued 48 hours prior to the procedure or at the discretion of the PI (e.g., aspirin, ibuprofen, low molecular weight heparin \[LMWH\] preparations)
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) within 6 weeks of screening
* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization. Women \>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization
* All lines of prior systemic therapy are permissible. Standard concurrent chemotherapy, immunotherapy, or targeted therapy are permissible
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Prior locoregional therapy to target lesion, including ablation of any modality, embolization, radiation, or surgery
* Patient may not be receiving any other investigational agents. Standard concurrent chemotherapy, immunotherapy, or targeted therapy will be allowed
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator
* Target lesions that involve the spinal column or calvarium
* Absolute neutrophil count \< 1000 mm\^3 within 6 weeks of screening
* Active infection
* Presence of confirmed pathologic fracture at the target lesion not amenable to percutaneous stabilization
* Lesions that involve a weight-bearing long bone of the lower extremity with the tumor causing \> 50% loss of cortical bone. Lesions involving the hands and feet

Where this trial is running

Houston, Texas

• M D Anderson Cancer Center — Houston, Texas, United States (RECRUITING)

Study contacts

• Principal investigator: Rahul A Sheth, MD — M.D. Anderson Cancer Center
• Study coordinator: Rahul A. Sheth, MD

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcoma